Last reviewed · How we verify
NCT01712672
Bacterial Arrangement on the Teeth
trial in Dental Plaque in 15 participants. Completed in 7 January 2016.
7 January 2016
Quick facts
| Lead sponsor | National Institute of Dental and Craniofacial Research (NIDCR) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 16 January 2013 |
| Primary completion | 7 January 2016 |
| Estimated completion | 7 January 2016 |
| Sites | 1 location across United States |
Conditions studied
- Dental Plaque — all drugs for Dental Plaque →
- Oral Health — all drugs for Oral Health →
- Periodontal Disease and Caries — all drugs for Periodontal Disease and Caries →
- Periodontal Disease — all drugs for Periodontal Disease →
Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Who can join
18 and older, any sex, with Dental Plaque or Oral Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Dental plaque is a coating of bacteria on the teeth. It contributes to poor dental health and diseases such as gingivitis, cavities and periodontal disease. Researchers who study plaque know that many different types of oral bacteria stick to each other in test-tube experiments. However, it is not clear if these interactions occur in natural dental plaque. By studying how bacteria interact, researchers can better understand how bacteria come together and grow to form plaque. Objectives: \- To look at how bacteria interact with one another to form dental plaque. Eligibility: \- Healthy nonsmoking volunteers at least 18 years of age. Design: * Participants will be screened with a medical history and dental exam. They will also have dental impressions taken for a stent (a device similar to Invisalign(SqrRoot) braces). * Participants will wear the stent for up to 8 hours a day on selected study visit days. It will contain enamel chips made from sterilized human teeth. The mouth bacteria will stick to the chips and grow. Chips will be taken out of the stent twice during these study visit days. * Participants will have other study visits to provide saliva and plaque samples. They will also have gum swabs to collect bacteria. * Some participants may have a second set of study visits. At these visits, they will chew gum to increase their saliva production. Afterwards, they will wear the stent with the enamel chips for 4 hours. Samples from the stent will be taken once on these study visit days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01712672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dental Plaque
Currently open trials in the same condition.
- NCT07088666 — 0.2% Chlorhexidine vs MicroRepair ABX in Gingivitis · NA · recruiting
- NCT07356869 — Probiotic-Based Versus Ethyl Lauroyl Arginate-Containing Mouthwashes on Streptococcus Mutans Counts, Dental Plaque Accum · NA · recruiting
- NCT07119840 — Comparison Of Clinical Effects Of Listerine And Chlorhexidine Mouth Wash In Patients Undergoing Fixed Orthodontic Treatm · NA · recruiting
- NCT07115784 — Clinical Efficacy of Chlorhexidine Varnish in Reducing Gingival Hyperplasia, Plaque Accumulation, and White Spot Lesions · NA · recruiting
- NCT07029360 — Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy · NA · recruiting
Other National Institute of Dental and Craniofacial Research (NIDCR) trials
Trials by the same sponsor.
- NCT07281456 — Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease · Phase 2 · recruiting
- NCT05735015 — PTH-independent Effects of Encaleret · Phase 2 · completed
- NCT05509595 — Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia · Phase 2 · completed
- NCT05419050 — Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia · Phase 2 · completed
- NCT04496960 — Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01712672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Dental and Craniofacial Research (NIDCR)
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01712672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing